A novel TLR9 agonist as experimental therapy for prostate cancer

被引:0
|
作者
Rayburn, E. R. [1 ]
Wang, H. [1 ]
Zhang, R. [1 ]
机构
[1] Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, Birmingham, AL USA
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
引用
收藏
页码:211 / 212
页数:2
相关论文
共 50 条
  • [31] Clocking on for TLR9
    Kirsty Minton
    Nature Reviews Immunology, 2012, 12 : 228 - 229
  • [32] NASH and TLR9
    Hugh Thomas
    Nature Reviews Gastroenterology & Hepatology, 2016, 13 (3) : 124 - 124
  • [33] Turning on TLR9
    Ahmad, Sharon
    NATURE REVIEWS IMMUNOLOGY, 2007, 7 (07) : 496 - 496
  • [34] Correlation among Tonsillar TLR9 Expression, TLR9 SNP and Clinical Outcomes of Tonsillectomy with Steroid Pulse Therapy
    Sato, Daisuke
    Suzuki, Yusuke
    Kano, Tatsuya
    Suzuki, Hitoshi
    Yokoi, Hidenori
    Horikoshi, Satoshi
    Ikeda, Katsuhisa
    Tomino, Yasuhiko
    RECENT ADVANCES IN TONSILS AND MUCOSAL BARRIERS OF THE UPPER AIRWAYS, 2011, 72 : 190 - 190
  • [35] TLR9 agonists
    Hirsh, Vera
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S201 - S201
  • [36] Role of immunostimulatory DNA and TLR9 in gene therapy
    Yasuda, Kei
    Wagner, Hermann
    Takakura, Yoshinobu
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2006, 23 (02): : 89 - 109
  • [38] Novel monoclonal antibodies for the detection of human TLR9
    Acuff, Nicole V.
    Oida, Takatoku
    Divekar, Anagha A.
    Yang, Xifeng
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [39] Combination of TLR9 agonist lefitolimod/MGN1703 with checkpoint inhibitors for cancer immunotherapy.
    Schmidt, Manuel
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [40] Aacetaminophen hepatotoxicity is dependent on TLR9 and can be reduced by a TLR9 antagonist
    Mahmood, Shamail
    Watanabe, Azuma
    Sohail, Muhammad A.
    Flavell, Richard A.
    Mehal, Wajahat Z.
    GASTROENTEROLOGY, 2008, 134 (04) : A752 - A752